Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
Date:2/12/2009

ated from the collaboration with Bayer, reimbursement of Onyx's shared marketing costs related to Nexavar and Nexavar royalty revenue. Onyx's 50% share of collaboration research and development expenses is included in the research and development expense line item.

In addition, all prior periods from January 1, 2006 through September 30, 2008 will be reclassified to conform to this new guidance and will be presented in Onyx's Form 8-K to be filed with the Securities and Exchange Commission prior to the fourth quarter and full year 2008 financial results call on February 23, 2009. For additional information on the structure of the company's new Statement of Operations, please visit the investor section of Onyx's website at http://www.onyx-pharm.com/wt/page/investors.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
2. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
3. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
4. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
5. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
6. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
9. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
10. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
11. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 CarePoint Health is ... Leigh Montes, MD, has joined our expanded Bariatric ... Hospital. Our system welcomes Dr. Montes to the ... surgical weight loss center, helps patients achieve long-term ... surgery procedures, including Gastric Sleeve, Gastric Bypass, LAP-BAND ...
(Date:9/16/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... can delay a man,s onset of age-related high blood pressure ... pressure naturally increases as people grow older and their arteries ... don,t start drifting toward high blood pressure until their mid-50s. ... early signs of high blood pressure in their mid-40s, researchers ...
(Date:9/16/2014)... discoveries everyday, but that doesn,t mean the findings are ... example, the neonatal mortality rate is 10 times higher ... that applying an inexpensive topical solution of chlorhexidine to ... rate by 24 percent, many Indian parents did not ... not that we don,t have solutions to solve major ...
(Date:9/16/2014)... The Columbia University College of Dental Medicine ... in Diversity (HEED) award from INSIGHT Into Diversity ... higher education. As a recipient of the annual ... universities that demonstrate an outstanding commitment to diversity ... other recipients in INSIGHT Into Diversity magazine,s November ...
(Date:9/16/2014)... Size is relative, especially to people who tend to ... University Medical Center in the US found that seven ... weighs. People of normal weight make this mistake much ... tend to misjudge their children,s size, as youngsters misjudge ... now at Weill-Cornell Medical College, in a study in ...
Breaking Medicine News(10 mins):Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2
... , MONDAY, March 21 (HealthDay News) -- A woman,s use ... risk of respiratory problems in her children, according to a ... use of birth control pills may increase the risk of ... said the authors of the new study. The researchers ...
... MONDAY, March 21 (HealthDay News) -- While the majority of ... generally satisfied years later, almost 40 percent are saddled with ... removed, a small, new Belgian study reveals. The finding ... the University of California, San Francisco that suggested gastric bypass ...
... Rockville, Md., March 21, 2011 As part of ... Pharmacopeial Convention (USP) is working with the Food and ... (CHPA) to update quality standards for widely used medicines ... an ambitious, long-term effort to assess written (or documentary) ...
... Health Sciences University is enrolling patients in a federally funded ... progression of kidney disease. "The question is, if you ... said Dr. Laura Mulloy, Chief of the GHSU Section of ... Intervention Trial, or SPRINT, funded by the National Institutes of ...
... change the balance of bacteria that naturally live in the ... Brain, Behavior, and Immunity . "These bacteria ... the immune response," said lead researcher Michael Bailey. ... number of gut microorganisms, according to scientists from The Ohio ...
... March, 2011 Alcohol use during pregnancy is common ... and development of exposed offspring. Despite warnings from the ... contemplating pregnancy, a recent survey by the National Birth ... drank alcohol at some time during their pregnancy, with ...
Cached Medicine News:Health News:Moms' Use of 'the Pill' Won't Raise Kids' Asthma Risk: Study 2Health News:40% of Gastric Banding Patients Have Complications 2Health News:40% of Gastric Banding Patients Have Complications 3Health News:40% of Gastric Banding Patients Have Complications 4Health News:Quality standards for widely used medicines strengthened 2Health News:Quality standards for widely used medicines strengthened 3Health News:Study examines whether lower blood pressure reduces kidney disease progression 2Health News:Adolescent offspring of women who drank alcohol during first trimester 2
(Date:9/16/2014)... , Sept. 16, 2014 Based ... closure market, Frost & Sullivan recognises Incisive Surgical ... for Customer Value Leadership. Incisive Surgical,s uniquely-designed, innovative ... technology that eliminates the need for patients to ... and staple removal  that may result in increased ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix ... focused on developing and commercializing therapeutic products for ... infectious diseases, announces the amendment and restatement of ... preferred stock and related warrants, as well as ... stock and warrant financing, to remove anti-dilution, price ...
(Date:9/16/2014)... , Sept. 16, 2014  DNAtrix, Inc., experts ... first patient was treated with the company,s lead ... interferon in a randomized, multicenter, open-label Phase Ib ... "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists ... initiation of our randomized Phase Ib study of ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... (OTC Bulletin Board: ACUR) (the "Company") today announced ... "Agreement"), with an,investor group comprised of Vivo Ventures ... L.P., GCE Holdings LLC and certain individual investors,(the ... Units ("Units") at a price of $1.08 per ...
... 20 Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned ... RLL has received approval from the U.S. Food ... and,Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 ... The Office of Generic Drugs, U.S. Food and ...
Cached Medicine Technology:Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 2Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate 3Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Medicine Products: